Cara Therapeutics' Stock Buoyed By Positive Korsuva Data For Post-Op Pain

28 Jun 2018

• By Sten Stovall

Cara Therapeutics will discuss its options with regulators after positive top-line data from adaptive Phase II/III trial of its Korsuva drug in patients undergoing abdominal surgeries met its prime endpoint and sent the biotech's stock higher.

Laparoscopic equipment — Phase II/III Korsuva trial met its primary endpoint in patients undergoing abdominal surgeries • Source: Shutterstock

The market for non-addictive analgesics was in the minds of investors who sent shares in Cara Therapeutics Inc. sharply higher this week on news its investigational drug Korsuva (CR845/difelikefalin) in a Phase II/III trial met its primary endpoint by showing statistically significant reduction in pain intensity in patients undergoing abdominal surgery.

The randomized, placebo-controlled study involved 228 patients who underwent ventral hernia surgery and 216 patients who had a hysterectomy. The treatment also succeeded in reducing nausea and vomiting after surgery.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.